
浏览全部资源
扫码关注微信
1.甘肃中医药大学 基础医学院,兰州 730000
2.西安交通大学 药学院,西安 710061
3.西安市中医医院,西安 710021
[第一作者] 杨硕,在读硕士,从事方剂配伍研究,E-mail:734916256@qq.com
*窦建卫,博士,副教授,副主任医师,从事中药复方抗癌药效物质基础研究,E-mail:djw@mail.xjtu.edu.cn
收稿日期:2019-05-16,
网络出版日期:2019-08-02,
纸质出版日期:2020-03-05
移动端阅览
杨硕, 李康乐, 朱中博, 等. 阳和汤含药血清通过p38/STAT3信号通路对乳腺癌MCF-7细胞凋亡的影响[J]. 中国实验方剂学杂志, 2020,26(5):6-10.
Shuo YANG, Kang-le LI, Zhong-bo ZHU, et al. Effect of Serum Containing Yanghetang on Apoptosis of MCF-7 Cells in Breast Cancer Through p38/STAT3 Signaling Pathway[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(5): 6-10.
杨硕, 李康乐, 朱中博, 等. 阳和汤含药血清通过p38/STAT3信号通路对乳腺癌MCF-7细胞凋亡的影响[J]. 中国实验方剂学杂志, 2020,26(5):6-10. DOI: 10.13422/j.cnki.syfjx.20192222.
Shuo YANG, Kang-le LI, Zhong-bo ZHU, et al. Effect of Serum Containing Yanghetang on Apoptosis of MCF-7 Cells in Breast Cancer Through p38/STAT3 Signaling Pathway[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(5): 6-10. DOI: 10.13422/j.cnki.syfjx.20192222.
目的:
2
以有丝分裂原激活蛋白激酶(p38)/信号传导与转录激活因子3(STAT3)信号通路为基础,探究阳和汤含药血清对乳腺癌MCF-7细胞凋亡的影响。
方法:
2
制备含生药1 g·mL
-1
的阳和汤药液,将SD大鼠随机分为空白组(蒸馏水),阳和汤高、中、低剂量组(24,12,6 g·kg
-1
),灌胃后制备阳和汤含药血清,用10%含药血清干预MCF-7细胞,通过细胞增殖及细胞毒性实验(CCK-8)检测阳和汤含药血清对MCF-7细胞增殖的影响;通过流式细胞术检测MCF-7细胞的凋亡情况;通过蛋白免疫印迹法(Western blot)检测p38和STAT3蛋白的表达情况;通过实时荧光定量聚合酶链式反应(Real-time PCR)检测B细胞淋巴瘤/白血病-xl(Bcl-xl)及生存素(Survivin) mRNA表达的情况。
结果:
2
CCK-8实验显示,与空白组比较,阳和汤含药血清抑制MCF-7细胞增殖,且呈时间与剂量依赖性。其中高剂量组抑制作用最为明显,不同时间抑制率分别达到38%,45%,54%(
P
<
0.01);流式细胞术实验表明,与空白组比较,阳和汤含药血清中、高剂量组细胞凋亡率明显增加,且呈剂量依赖性,凋亡率分别达11.6%,16.5%(
P
<
0.05,
P
<
0.01);Western blot表明,与空白组比较,阳和汤中、高剂量含药血清组p38,STAT3蛋白表达减少(
P
<
0.01),且呈剂量依赖性;Real-time PCR实验表明,与空白组比较,阳和汤中、高剂量含药血清组Bcl-xl,Survivin mRNA表达减少(
P
<
0.05,
P
<
0.01),且呈剂量依赖性。
结论:
2
阳和汤含药血清可以促进乳腺癌MCF-7细胞的凋亡,可能与p38/ STAT3信号通路有关。
Objective:
2
To investigate the effect of serum containing Yanghetang (YHT) on the apoptosis of MCF-7 cells in breast cancer based on the mitogen-activated protein kinase (p38)/signal transduction and transcriptional activator 3 (STAT3) signal pathway.
Method:
2
YHT liquid with crude drug 1 g·mL
-1
was prepared. Female SD rats were randomly divided into control group (distilled water)
and high
medium and low-dose YHT groups (24
12
6 g·kg
-1
). YHT-medicated serum was prepared
and 10%medicated serum was used to intervene MCF-7 cells. Cell proliferation and cytotoxicity assay (CCK-8) was used to detect the effect of serum containing YHT on MCF-7 cell proliferation
apoptosis of MCF-7 cells was detected by flow cytometry protein expressions of p38 and STAT3 were detected by Western blot
Quantitative Real-time PCR (Real-time PCR) was used to detect the expressions of B-cell lymphoma/leukemia-xl(Bcl-xl) and Survivin mRNA.
Result:
2
CCK-8 assay showed that YHT serum inhibited the proliferation of MCF-7 cells in a time and dose-dependent manner compared with the blank group. The inhibitory effect was most obvious in the high-dose group
with the inhibition rates of 38%
45%and 54%at different time points (
P
<
0.01). Flow cytometry showed that
compared with the blank group
the apoptosis rate in the medium and high-dose groups increased significantly in a dose-dependent manner
with the apoptosis rates at 11.6%and 16.5%respectively (
P
<
0.05
P
<
0.01). Western blot analysis showed that
compared with the blank group
the expressions of p38 and STAT3 protein was decreased in high
medium-dose YHT groups (
P
<
0.01) in a dose-dependent manner. Compared with the blank group
the expressions of Bcl-xl and Survivin mRNA were decreased in high
medium-dose YHT groups (
P
<
0.05
P
<
0.01) in a dose-dependent manner.
Conclusion:
2
YHT serum can promote the apoptosis of MCF-7 cells in breast cancer
which may be related to the p38/ STAT3 signaling pathway.
O GINSBURG , F BRAY , M P COLEMAN , et al . The global burden of women' s cancers: a grand challenge in global health [J]. Lancet , 2017 , 389 ( 10071 ): 847 - 860 .
F BRAY , J FERLAY , I SOERJOMATARAM , et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2018 , 68 ( 6 ): 394 - 424 .
X JIANG , H TANG , T CHEN . Epidemiology of gynecologic cancers in China [J]. J Gynecol Oncol , 2018 , 29 ( 1 ): e7 .
D WEN , X WEN , Y YANG , et al . Urban rural disparity in female breast cancer incidence rate in China and the increasing trend in parallel with socioeconomic development and urbanization in a rural setting [J]. Thoracic Cancer , 2017 , 9 ( 2 ): 262 - 272 .
J S LAWSON , W H GUNZBURG , N J WHITAKER . Viruses and human breast cancer [J]. Future Microbiol , 2007 , 1 ( 1 ): 33 - 51 .
张欣萌 , 郝云 , 吴红彦 , 等 . “化气成形”理论对乳腺癌辨证论治的指导意义 [J]. 国医论坛 , 2016 , 31 ( 5 ): 14 - 15 .
窦建卫 , 任翠翠 , 郝云 , 等 . 阳和汤对裸鼠荷人乳腺癌组织中CD90表达的影响及其抑瘤作用 [J]. 世界中医药 , 2015 , 10 ( 3 ): 391-393,398 .
A IWANMARU , S SZYMANSKI , E IWADO , et al . A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo [J]. Oncogene , 2006 , 26 ( 17 ): 2435 - 2444 .
康红钰 , 王雁梅 , 杜钢军 , 等 . 阳和汤血清增强阿霉素对MCF-7肿瘤细胞抑制作用机制的研究 [J]. 中国实验方剂学杂志 , 2011 , 17 ( 18 ): 196 - 199 .
王力倩 , 李仪奎 , 符胜光 , 等 . 血清药理学方法研究探索 [J]. 中药药理与临床 , 1997 ( 3 ): 30 - 32 .
郑荣寿 , 孙可欣 , 张思维 , 等 . 2015年中国恶性肿瘤流行情况分析 [J]. 中华肿瘤杂志 , 2019 , 41 ( 1 ): 19 - 28 .
吴峰 . 阳和汤治疗乳岩之初探 [J]. 四川中医 , 2008 , 26 ( 12 ): 30 - 32 .
孟祥悦 . 加味阳和汤治疗乳腺癌骨转移的临床疗效 [J]. 中外医疗 , 2017 , 36 ( 26 ): 159 - 161 .
陈英 , 张松卿 , 吴仲玖 , 等 . 阳和汤加味治疗乳房疾病验案2则 [J]. 浙江中医杂志 , 2005 , 40 ( 2 ): 82 - 82 .
窦建卫 , 黄芊 , 赵天一 , 等 . 阳和汤对三阴性乳腺癌裸鼠移植瘤生长及IL-6、MMP-9表达的影响 [J]. 中国现代医药杂志 , 2016 , 18 ( 12 ): 1 - 4 .
E F WAGNER , A R NEBREDA . Signal integration by JNK and p38 MAPK pathways in cancer development [J]. Nat Rev Cancer , 2009 , 9 ( 8 ): 537 - 549 .
郑炜望 . STAT3与肿瘤关系的研究综述 [J]. 现代中西医结合杂志 , 2015 , 24 ( 27 ): 3074 - 3078 .
K RAVICHANDRAN , A TYAGI , G DEEP , et al . Interleukin-1 beta-induced iNOS expression in human lung carcinoma A549 cells: involvement of STAT and MAPK pathways [J]. Indian J Exp Biol , 2011 , 49 ( 11 ): 840 - 847 .
0
浏览量
19
下载量
6
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621